Treatment of diabetes mellitus: Implications of the use of oral agents

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages

  Rao, S V ^a   Bethel, M A ^a   Feinglos, M N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIMEPIRIDE; INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0032716835     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70032-3     Document Type: Conference Paper

References (45)

1. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J 1999;138;S366-75.
2. Clark CM Jr, Perry RC. Type 2 diabetes and macrovascular disease: epidemiology and etiology. Am Heart J 1999;138;S330-3.
3. Stout RW, Vallance-Owen J. Insulin and atheroma. Lancet 1969;1:1078-80.
4. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from 2 population studies in Finland. Diabetes Care 1979;2:131-41.
5. Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease in a middle-aged population. Diabetologia 1980;19:205-10.
6. Wellborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60.
7. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1988;37(suppl 1):S1-9.
8. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996;45(suppl 3):45-6.
9. Zunker P, Schick A, Buschmann HC, et al. Hyperinsulinism and cerebral microangiopathy. Stroke 1997;27:219-23.
10. Sobel BE. Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation 1996;93:1613-5.
11. Stout RW. Insulin and atheroma: 20-yr. perspective. Diabetes Care 1990;13:631-54.
12. Folsom AR, Szklo M, Stevens J, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes: the Atherosclerosis Risk In Communities (ARIC) Study. Diabetes Care 1997;20:935-42.
13. Bonora E, Targher G, Zenere MB, et al. Relationship between fasting insulin and cardiovascular risk factors already present in young men: the Verona Young Men Atherosclerosis Risk Factors Study. Eur J Clin Invest 1997;27:248-54.
14. Haffner SM, Miettinen H. Insulin resistance implications for Type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-62.
15. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755-72.
16. Stumvoli MS, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in NIDDM. N Engl J Med 1995;333:550-4.
17. Cush K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.
18. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
19. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
20. Grant PJ. The effects of high and medium dose metformin therapy on cardiovascular risk factors in patients with Type II diabetes. Diabetes Care 1996;19:64-6.
21. Davidson MB, Peters AL. An overview of metformin in the treatment of Type 2 diabetes mellitus. Am J Med 1997;102:99-109.
22. Fanghanel G, Sanchez-Reyes L, Trujillo C, et al. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996;19:1185-9.
23. Golay A, Guillet-Dauphine N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 1995;11:63-7.
24. Spencer CM, Markham A. Troglitazone. Drugs 1997;54:89-101.
25. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes 1996;45:1661-9.
26. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-9.
27. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9.
28. Berkowitz K, Peters R, Kjos S, et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 1996;45:1572-9.
29. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
30. Raskin P, Graveline JF. Efficacy of troglitazone in combination with insulin in NIDDM: slide in paper presentation at 57th Annual Meeting and Scientific Sessions of American Diabetes Association; June 21-24, 1997; Boston, Mass.
31. Rezulin (troglitazone). Package insert, Parke-Davis Pharmaceuticals, Morris Plains, New Jersey, June 1999.
32. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442-8.
33. Inoue I, Takahashi K, Noji S, et al. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1997;36:143-51.
34. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea. Diabetes Care 1996;19:1194-9.
35. Goldsberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-56.
36. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995;28:S139-46.
37. Wolfenbuttel BHR, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med 1996;72:657-62.
38. Dills DG, Schneider J. Clinical evaluation of glimepiride and glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996;28:426-9.
39. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular mortality, and the UGDP. Am Heart J 1999;138;S346-52.
40. Jollis JG, Simpson RJ Jr, Cascio WE, et al. The relation between sulfonylurea therapy, complications, and outcome for elderly acute myocardial infarction patients. Am Heart J 1999;138;S376-80.
41. Howes LG, Sundaresan P, Lykos D. Cardiovascular effects of oral hypoglycemic drugs. Clin Exp Pharmacol Physiol 1996;23:2201-6.
42. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996;39:503-14.
43. Schotborgh CE, Wilde AAM. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997;34:73-80.
44. Smits P, Bijlstra PJ, Russel FG, et al. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract 1996;31(suppl):S55-9.
45. Dillis DG, Schneider J. Clinical evaluation of glimepiride and glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996;28:426-9.